46
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease.

      Ocular Immunology and Inflammation
      Administration, Oral, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Implants, Drug Therapy, Combination, Female, Fluocinolone Acetonide, administration & dosage, Glucocorticoids, Humans, Injections, Intravenous, Male, Prednisone, Recurrence, Retinal Detachment, complications, drug therapy, Retrospective Studies, Treatment Outcome, Uveomeningoencephalitic Syndrome, Vitreous Body, Young Adult

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To describe the use of fluocinolone acetonide implants (Retisert) in Vogt-Koyanagi-Harada disease (VKH). Interventional case series. Retrospective review of medical records. Two patients with VKH requiring high-dose systemic corticosteroid therapy to control their inflammation and bilateral serous retinal detachments received bilateral fluocinolone acetonide implants. Upon tapering of systemic corticosteroids, one patient had recurrent serous retinal detachments and the other patient's anterior chamber and vitreous inflammation returned. The authors' experience with fluocinolone acetonide implants in VKH has been mixed with an inability to fully taper off of systemic corticosteroids.

          Related collections

          Author and article information

          Comments

          Comment on this article